Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, announced today it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
佛羅里達州龐特韋德拉，2024年9月23日 / PRNewswire/ - Cadrenal Therapeutics，Inc.（納斯達克：CVKD），一家處於後期階段的生物製藥公司，正在開發一種新型維生素K拮抗劑（VKA）tecarfarin，旨在成爲一種更優異和更安全的慢性抗凝劑，專爲依賴華法林的植入式心臟設備患者或罕見心血管疾病患者設計。該公司今天宣佈，將參加在2024年10月1日星期二通過網絡直播舉行的Lytham Partners 2024年秋季投資者大會，並與投資者舉行一對一會議。
Company Webcast
公司網絡研討會
Cadrenal's webcast presentation will begin at 2:00 pm ET on Tuesday, October 1. Access will be available via the conference home page at or directly at . The webcast will also be available for replay following the event.
Cadrenal的網絡直播彙報將於10月1日星期二美國東部時間下午2:00開始。可通過大會主頁或直接進行訪問。網絡直播還將在活動結束後提供回放。
One-on-one Meetings
一對一會議
Cadrenal management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting, please contact Lytham Partners at [email protected] or register for the event at .
Cadrenal管理團隊將在整個活動期間參加一對一的虛擬會議。若想安排會議，請聯繫Lytham Partners，郵箱爲[email protected]，或在活動註冊頁面註冊。
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company boldly challenging the status quo by innovating a new anticoagulant to elevate care for underserved patients. The company is developing the vitamin K antagonist (VKA) tecarfarin, designed to be a superior and safer anticoagulant for individuals with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its prevalent side effects and cumbersome dosing. With its innovation, the company aims to unburden these patients and their healthcare providers from warfarin's many challenges.
關於Cadrenal Therapeutics，Inc.
Cadrenal Therapeutics是一家處於後期階段的生物製藥公司，挑戰現狀，通過創新一種新的抗凝劑提升爲服務不足的患者提供保健。該公司正在開發維生素K拮抗劑（VKA）tecarfarin，旨在成爲一種更爲優異和更安全的抗凝劑，適用於植入心臟設備或罕見心血管疾病患者。Cadrenal致力於改善這些患者的預後，降低重大事件的發生率，這些患者除了華法林之外，缺乏慢性抗凝劑選擇，後者以其普遍的副作用和繁瑣的服用方式而聞名。憑藉其創新，公司旨在減輕這些患者及其醫療服務提供者因華法林所帶來的許多挑戰。
Cadrenal's late-stage drug candidate tecarfarin is a new VKA anticoagulant that is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin. Tecarfarin received an orphan drug designation for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal trials along with clinical and commercial partnership opportunities. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit .
Cadrenal的後期藥物候選者tecarfarin是一種新型維生素K拮抗劑慢性抗凝劑，預計將導致較華法林更少的不良事件，如中風，心臟病發作，出血和死亡。 Tecarfarin已獲得孤兒藥物資格，適用於植入左心室輔助裝置（LVADs）的心力衰竭患者，以及心房顫動併發晚期腎臟病患者的孤兒藥物和快速跟蹤資格。Cadrenal正在機會主義地進行關鍵試驗，以及臨床和商業合作伙伴關係機會。該公司計劃還包括在機械性瓣膜患者中研究tecarfarin，這些患者出現抗凝困難。 更多訊息，請訪問。
For more information, please contact:
更多信息，請聯繫：
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
[email protected]
Cadrenal Therapeutics:
CFO馬修·索特（Matthew Szot）
858-337-0766
[email protected]
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
[email protected]
投資者：
Lytham Partners, LLC
Robert Blum，管理合夥人
602-889-9700
[email protected]
SOURCE Cadrenal Therapeutics, Inc.
來源：Cadrenal Therapeutics，Inc。
